Literature DB >> 21098779

Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA).

Adam J Rose1, Elaine M Hylek, Al Ozonoff, Arlene S Ash, Joel I Reisman, Dan R Berlowitz.   

Abstract

BACKGROUND: Oral anticoagulation is safer and more effective when patients receive high-quality care. However, there have been no prior efforts to measure quality of oral anticoagulation care or to risk adjust it to ensure credible comparisons. Our objective was to profile site performance in the Veterans Health Administration (VA) using risk-adjusted percent time in therapeutic range (TTR). METHODS AND
RESULTS: We included 124 551 patients who received outpatient oral anticoagulation from 100 VA sites of care for indications other than valvular heart disease from October 1, 2006, to September 30, 2008. We calculated TTR for each patient and mean TTR for each site of care. Expected TTR was calculated for each patient and each site based on the variables in the risk adjustment model, which included demographics, comorbid conditions, medications, and hospitalizations. Mean TTR for the entire sample was 58%. Site-observed TTR varied from 38% to 69% or from poor to excellent. Site-expected TTR varied from 54% to 62%. Site risk-adjusted performance ranged from 18% below expected to 12% above expected. Risk adjustment did not alter performance rankings for many sites, but for other sites, it made an important difference. For example, the site ranked 27th of 100 before risk adjustment was one of the best (risk-adjusted rank, 7). Risk-adjusted site rankings were consistent from year to year (correlation between years, 0.89).
CONCLUSIONS: Risk-adjusted TTR can be used to profile the quality of outpatient oral anticoagulation in a large, integrated health system. This measure can serve as the basis for quality measurement and quality improvement efforts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098779     DOI: 10.1161/CIRCOUTCOMES.110.957738

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  42 in total

Review 1.  Balancing ischaemia and bleeding risks with novel oral anticoagulants.

Authors:  Usman Baber; Ioannis Mastoris; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2014-11-04       Impact factor: 32.419

2.  Organizational characteristics of high- and low-performing anticoagulation clinics in the Veterans Health Administration.

Authors:  Adam J Rose; Beth Ann Petrakis; Patricia Callahan; Scott Mambourg; Dimple Patel; Elaine M Hylek; Barbara G Bokhour
Journal:  Health Serv Res       Date:  2012-02-02       Impact factor: 3.402

3.  Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation.

Authors:  John A Dodson; Andrew Petrone; David R Gagnon; Mary E Tinetti; Harlan M Krumholz; J Michael Gaziano
Journal:  JAMA Cardiol       Date:  2016-04-01       Impact factor: 14.676

4.  Genetic determinants of variability in warfarin response after the dose-titration phase.

Authors:  Otito F Iwuchukwu; Andrea H Ramirez; Yaping Shi; Erica A Bowton; Vivian K Kawai; Jonathan S Schildcrout; Dan M Roden; Joshua C Denny; C Michael Stein
Journal:  Pharmacogenet Genomics       Date:  2016-11       Impact factor: 2.089

5.  Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients.

Authors:  Jenna M Faircloth; Kristin M Miner; Tarek Alsaied; Nicole Nelson; Julie Ciambarella; Tomoyuki Mizuno; Joseph S Palumbo; Alexander A Vinks; Gruschen R Veldtman
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

6.  Capsule commentary on Paradise et al., Outcomes of anticoagulation therapy in patients with mental health conditions.

Authors:  Ankur Gupta
Journal:  J Gen Intern Med       Date:  2014-06       Impact factor: 5.128

Review 7.  A Practical Guide to Using the Positive Deviance Method in Health Services Research.

Authors:  Adam J Rose; Megan B McCullough
Journal:  Health Serv Res       Date:  2016-06-28       Impact factor: 3.402

Review 8.  Potential use of NOACs in developing countries: pros and cons.

Authors:  Durga Bista; Leanne Chalmers; Luke Bereznicki; Gregory Peterson
Journal:  Eur J Clin Pharmacol       Date:  2014-05-11       Impact factor: 2.953

9.  Outcomes of anticoagulation therapy in patients with mental health conditions.

Authors:  Helen T Paradise; Dan R Berlowitz; Al Ozonoff; Donald R Miller; Elaine M Hylek; Arlene S Ash; Guneet K Jasuja; Shibei Zhao; Joel I Reisman; Adam J Rose
Journal:  J Gen Intern Med       Date:  2014-02-19       Impact factor: 5.128

10.  Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study.

Authors:  Shadi Yaghi; Eva Mistry; Ava L Liberman; James Giles; Syed Daniyal Asad; Angela Liu; Muhammad Nagy; Ashutosh Kaushal; Idrees Azher; Brian Mac Grory; Hiba Fakhri; Kiersten Brown Espaillat; Hemanth Pasupuleti; Heather Martin; Jose Tan; Manivannan Veerasamy; Charles Esenwa; Natalie Cheng; Khadean Moncrieffe; Iman Moeini-Naghani; Mithilesh Siddu; Erica Scher; Tushar Trivedi; Aaron Lord; Karen Furie; Salah Keyrouz; Amre Nouh; Christopher R Leon Guerrero; Adam de Havenon; Muhib Khan; Nils Henninger
Journal:  Stroke       Date:  2020-08-06       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.